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ABSTRACT 
 
The present study aimed to develop the new method for the estimation and validation of tenofovir in pure 
form and in pharmaceutical dosage form by RP-HPLC. The chromatogram of tenofovir was developed 
through column (Hyper ODS2 C18), UV detection at 260 nm at a flow rate of 1.2 ml/min with Methanol and 
Phosphate buffer (90:10) as mobile phase. The method was validated by various validation parameters such 
as accuracy, precision, linearity, specificity as per the ICH guidelines. A linearity range and retention time of 
Tenofovir were found to be 20-110 µg/ml and 2.1 min respectively. The % RSD of the Tenofovir was found 
to be 0.7. The % recovery was obtained as 99.7% for standard and 96.32% for tablets. This method was 
simple, accurate, precise and sensitive. Hence, the developed method was employed for the routine analysis 
of Tenofovir in the pharmaceutical dosage form. 
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INTRODUCTION 
Tenofovir disoproxil fumarate (TDF) is chemically 9-
((R)-2- ((bis (((isopropoxycarbonyl) oxy] methoxy) 
phosphinyl) methoxy) propyl) adenine [1,2]. It is an an-
tiretroviral drug used to treat AIDS and hepatitis-B. 
TDF (Figure 1) is an active form of tenofovir that ex-
ists as a foremost form due to its lesser oral bioavail-
ability of tenofovir. TDF is available as a fixed-dose 
combination with numerous antiretrovirals such as 
Efavirenz, Cobicistat, Emtricitabine, Elvitegravir, 
Lamivudine, Nevirapine, and Rilpivirine[3-6]. There-
fore, pharmaceutical analysis of TDF in bulk and in 
pharmaceutical dosage form by RP-HPLC is very im-
portant. There are very few analytical methods was 
reported for the estimation of tenofovir disoproxil 
such as sensitive determination of tenofovir in hu-
man plasma samples using RP-HPLC[7], development 
and validation of a sensitive LC-MS/MS method for 
the determination of TD in human plasma[8] . These 
methods are costly, time consuming as well as com-
plicated relatively than a simple RP-HPLC method. 
The aim of the present study was to develop the new 
method for the estimation and validation of tenofovir 
in pure form and in pharmaceutical dosage form by 
RP-HPLC. 
 
Figure 1: Structure of Tenofovir Fumarate 
MATERIALS AND METHODS 
Chemicals and reagents 
Tenofovir disoproxil fumarate and its tablets (Viread) 
were procured from Cipla pharmaceuticals. HPLC 
grade Methanol and Water were purchased from Le-
onid Chemicals Pvt Ltd and Merck Specialty Pvt Ltd. 
All the other chemicals and reagents used were of AR 
grade and purchased from Finar chemicals limited 
and Fisher Scientific India Pvt Ltd.  
Instrumentation 
High performance liquid chromatographic system 
(Analytical-2230) consisting of a pump, an injector, a 
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Column (Hyper ODS2 C18) equipped with UV-Visible 
detector and A2000 data system software was used. 
Ultrasonic cleanser was used for sonication and Elico 
pH meter was used for adjusting the pH of the buffer. 
Preparation of Tenofovir solution 
Weighed accurately about 100 mg of Tenofovir into 
100 ml volumetric flask, added with a minimum 
quantity of methanol, sonicated to dissolve and fur-
ther diluted to 100ml with methanol. 1ml of this so-
lution was diluted to 10 ml with methanol (100 µg ml-
1). Then it was filtered through 0.45μ PVDF mem-
brane filter by discarding the first 5 ml of the filtrate. 
Preparation of Buffer solution 
Weighed accurately about 3.4 g of Potassium dihy-
drogen phosphate and transferred into a 500 ml vol-
umetric flask. It was dissolved completely and the 
volume was made up to the mark with HPLC Water. 
Then the pH of the solution was adjusted to 5.0 with 
Glacial acetic acid. Finally, it was sonicated and fil-
tered through 0.45µm PVDF membrane filter. 
Method selection 
Selection of wavelength[9] 
Weighed accurately about 100mg of Tenofovir into 
100ml volumetric flask and was dissolved in 100ml 
of HPLC methanol. 0.6ml of this solution was diluted 
to 10 mL with methanol (60µg ml-1). Then it was fil-
tered through 0.45μ PVDF membrane filter by dis-
carding the first 5 ml of the filtrate. It was scanned on 
a UV-Visible spectrophotometer between wavelength 
ranges of 200 to 400 nm.  
Preparation of mobile phase[10] 
HPLC Methanol and Phosphate buffer (PH-5) were 
mixed in a 90:10 ratio and the resulting solution was 
sonicated on a sonicator for 30 min, then finally fil-
tered through a 0.45µm membrane filter and used. 
Preparation of standard drug stock solution 
Standard drug stock solution of Tenofovir disoproxil 
fumarate was prepared by dissolving accurately 100 
mg of the pure drug (Pharmaceutical grade) in 100 ml 
of HPLC grade Methanol to get 1mg/ml concentra-
tion. This solution was then sonicated, filtered and 
used to prepare further dilutions. 
General procedure for construction of the calibra-
tion curve[11] 
Aliquots of (0.2-1.5ml) the standard drug stock solu-
tions (1mg/ml) were transferred into series of 10 ml 
volumetric flasks and the volume was made up to the 
mark with methanol. This solution was sonicated, fil-
tered and 20µl of this solution was injected into HPLC 
and analyzed. The calibration curve was constructed 
from 20-150µg concentrations by plotting the peak 
area ratios of analyte versus the respective drug con-
centration. 
 
Method development 
Procedure for standard 
An accurately weighed portion of 100mg of TDF was 
dissolved in 50mL of methanol into a 100 ml volumet-
ric flask by sonication for 30 min with intermittent 
vigorous shaking. The final volume was made up to 
the mark with methanol to get a stock solution of 
1mg/ml. This solution was filtered through 0.45 μm 
filter. Aliquots of (0.3-0.7ml) the standard drug stock 
solutions (1mg/ml) were transferred into series of 10 
ml volumetric flasks and the volume was made up to 
the mark with methanol. All the concentrations were 
sonicated, filtered and 20µl of each solution was in-
jected into the column. All measurements were re-
peated 6 times for each concentration. 
Procedure for the tablets –standard addition 
method[12,13] 
20 tablets were accurately weighed and powdered. 
An accurately weighed portion of powder equivalent 
to 100 mg of TDF was extracted in 50 ml of methanol 
into a 100 ml volumetric flask by sonication for 30 
min with intermittent vigorous shaking. The final vol-
ume was made up to the mark with methanol to get a 
stock solution of 1mg/mL. This solution was filtered 
through 0.45 μm filter. Aliquots of (0.15-0.55 ml) the 
standard drug stock solutions (1mg/ml) were trans-
ferred into series of 10 ml volumetric flasks and 0.2ml 
of sample solution (tablets) was added to each flask 
and the volume was made up to the mark with meth-
anol. All the flasks were sonicated, filtered and 20µl 
of each solution was injected into the column. All 
measurements were repeated 6 times for each con-
centration. The amount of Tenofovir per tablet was 
calculated from the calibration curve. 
RESULTS AND DISCUSSIONS 
Absorption spectra 
The absorption spectra of the Tenofovir were meas-
ured in the range of 200-400nm against the blank so-
lution as shown in Figure 2. Tenofovir shows maxi-
mum absorbance at 260 nm and it was selected as the 
detection wavelength for the HPLC investigation. Lin-
earity, accuracy, precision, sensitivity and stability of 
the proposed methods were described and these de-
veloped methods applied to pharmaceutical prepara-
tions as tablets and obtained results were evaluated 
statistically.
 
Figure 2: UV spectrum of Tenofovir 
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Table 1: Statistical data of the regression equations 
for the determination of TDF 
Parameter TDF 
λmax 260nm 
Linearity range (µg/mL) 20-110 
Regression equation (y) -19198+20885x 
Intercept (b) -19198.6 
Slope (a) 20885.7 
Correlation coefficient (r) 0.999 
SD 660516 
LOD (µg /mL) 0.104 
LOQ (µg /mL) 0.316 
Optimized method 
Satisfactory elution of the peak for Tenofovir was ob-
tained with a solvent system of Methanol and Phos-
phate buffer of pH-5 adjusted with glacial acetic acid 
(90:10). Finally the method was optimized by select-
ing the mobile phase, HPLC Methanol: Phosphate 
buffer of pH-5 (90:10) due to its lower retention time 
and lower cost of solvents. 
Linearity and range 
Beer’s law range, regression equation and correlation 
coefficient determined for the given method are 
shown in Table 1. A linear relationship was found be-
tween the Peak area at λmax and the concentration of 
the drug in the range of (20-110µg ml-1) in the final 
measured volume of 10 ml. Regression analysis of 
Beer’s law plots at λmax reveals a good correlation. 
The graph shows negligible intercept and is de-
scribed by the regression equation, Y= aX + b (where 
a is the slope, b is the intercept and X is the concen-
tration of the measured solution in μg ml−1) obtained 
by the least-squares method. The calibration curve 
for the proposed methods is shown in Figure 3. 
 
Figure 3: Calibration curve of Tenofovir by HPLC 
Precision studies 
For standard 
The intra-day precision was determined by analyzing 
standard solutions of 30,50,70µg/ml (Figure 4) for 
six times on the same day while inter-day precision 
was determined by analyzing corresponding stand-
ards on the other day for 6 times and the results were 
shown in Table 2. 
 
For tablet 
The intra-day precision was determined by analyzing 
the tablet solutions of 35-75µg/ml, which were pre-
pared by using the standard addition method for six 
times on the same day and the results were shown in 
Table 2. 
 
Figure 4: HPLC spectrum of Tenofovir 
Table 2: Precision study of Tenofovir 
Sl.no. 
Concentra-
tion of 
Tenofovir 
(µg/ml) 
Intraday pre-
cision peak 
area 
Interday pre-
cision peak 
area 
1. 30 
632911.51 655475.68 
636302.65 590331.85 
610313.85 599643.68 
657647.92 644684.03 
632076.16 620312.42 
573104.47 618320.16 
2. 50 
991438.10 956091.89 
989633.22 942402.24 
961720.33 949925.62 
1004076.06 929423.79 
1010727.19 943264.03 
984621.29 938177.76 
3. 70 
1487887.15 1394955.95 
1431215.20 1407791.75 
1440358.49 1420146.69 
1429331.11 1398347.88 
1434687.78 1397881.67 
1433880.68 1430310.45 
Validation of the methods 
Procedure for the standard 
Samples of standard TDF were prepared and tested 
at three levels (30, 50, 70 µg/ml) according to the 
proposed method. The complete set of validation as-
says were performed for the standard drug in intra 
and inter days. The precision and accuracy of the pro-
posed method were tested by analyzing six replicates 
of the standard drug. The standard deviation, relative 
standard deviation, recovery and 95% confidence 
limits of the proposed method are recorded in Table 
3 & 4. The average percent recoveries obtained were 
quantitative (93.96–100.7%), indicating the good ac-
curacy of the method.[14]  
  
 I. Manojkumar et al., (2020) Int. J. Res. Pharm. Sci & Tech., 2(1), 17-24 
20  Rubatosis Publications | International Journal of Research in Pharmaceutical Sciences and Technology 
 
  
Table 3: Tenofovir tablet analysis 
Concentration (µg/ml) 
Peak area Average ± SD %RSD 
Standard Sample 
15 20 
668343.49 
667616.08 
± 
6448.82 
0.97 
659959.55 
660067.72 
668958.57 
675551.25 
672815.87 
25 20 
894270.69 
890695.56 
± 
26447.72 
2.97 
892690.34 
939895.73 
871019.73 
867807.49 
878489.40 
35 20 
1129817.70 
1100924.99 
± 
33357.18 
2.97 
1073399.67 
1140276.12 
1069100.42 
1070303.49 
1122652.51 
45 20 
1261498.08 
1250631.46 
± 
11969.26 
0.96 
1234830.97 
1247823.91 
1247707.88 
1244232.05 
1267695.88 
55 20 
1431897.31 
1435484.25 
± 
30538.71 
2.13 
1465355.78 
1426710.96 
1403244.45 
1407260.23 
1478436.77 
Table 4: Analysis of TDF in bulk powder by HPLC (n=6) intraday 
Method 
Conc µg/ml 
S.D Recovery  (%) PrecisionaR.S.D (%) 
Accuracy 
ER% 
Cofidence limitsb  (95%) 
Taken Found 
HPLC 
 
30 
30.61 
30.77 
29.52 
31.81 
30.57 
30.16 
28.00 
1.30 100.7 4.3 0.7 28.846-31.574 
50 
49.39 
49.30 
47.91 
50.02 
50.35 
49.05 
0.85 98.66 1.72 -1.34 48.438-50.222 
70 
71.97 
69.22 
69.67 
69.13 
69.39 
69.35 
1.08 99.6 1.55 -0.31 68.647-70.913 
n, number of determination, % R.S.D, %, percentage relative standard deviation; Er %, percentage relative error. aMean 
of six determinations.bConfidence limit at 95% confidence level and five degrees of freedom 
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Table 5: Analysis of TDF in bulk powder by HPLC (n=6) interday 
Method 
µg/ml 
S.D  
Recov-
ery 
(%) 
Preci-
siona 
R.S.D (%) 
Accuracy 
ER% 
Cofidence   limitsb 
(95%) Taken Added Found 
HPLC 
30 
31.70 
28.55 
29.00 
31.18 
30.00 
29.90 
1.21 100.16 4.04 0.166 
28.776-
31.324 
30 
50 
47.63 
46.95 
47.32 
46.30 
46.99 
46.74 
0.46 93.96 0.97 -6.04 
46.497-
47.463 
50 
70 
69.50 
70.14 
70.75 
69.67 
69.64 
71.26 
0.70 100.22 1.007 0.228 
69.417-
70.903 
70 
Table 6: Evaluation of accuracy and precision of TDF tablets by standard addition method  
(n= 6) 
Method 
µg/ml 
S.D  
Recovery 
(%) 
Precisiona 
R.S.D (%) 
Accuracy 
ER% 
Cofidence   limitsb (95%) 
Taken Added Found 
HPLC 20 
15 
33.30 
32.88 
32.88 
33.33 
33.65 
33.52 
0.320 95.02 0.962 -4.97 32.924-33.596 
25 
44.55 
44.47 
46.83 
43.39 
43.23 
43.77 
1.320 98.6 2.97 -1.4 42.985-45.755 
35 
54.65 
52.00 
55.15 
51.71 
51.77 
54.30 
1.590 96.8 2.98 -3.16 51.592-54.928 
45 
62.85 
61.52 
62.17 
62.16 
61.99 
63.16 
0.597 95.84 0.95 -4.15 61.674-62.926 
55 
71.34 
73.01 
71.08 
69.91 
70.11 
73.66 
1.523 95.34 2.12 -4.65 69.912-  73.108 
n, number of determination, % R.S.D, %, percentage relative standard deviation; Er %, percentage relative error. aMean 
of six determinations.bConfidence limit at 95% confidence level and five degrees of freedom 
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Procedure for the tablet: The proposed method was 
applied to the determination of TDF in commercial 
tablets. The accuracy of the proposed method is eval-
uated by applying standard addition technique, in  
which variable amounts of a previously analyzed por-
tion of the standard drug were added to the formula-
tion and the results are tabulated in Table 8. Six rep-
licates determinations were made. Satisfactory re-
sults were obtained for drug and were in a good 
agreement with the label claims (Table 5 & Table 6). 
The results were reproducible with low R.S.D. values. 
The average percent recoveries obtained were quan-
titative (95.02–98.60%), indicating the good accu-
racy of the method. The results of analysis of the com-
mercial tablets and the recovery study of drug sug-
gested that there is no interference from any excipi-
ents which are present in tablets. 
CONCLUSION 
An efficient high performance liquid chromato-
graphic method was developed and validated for the 
estimation of Tenofovir in pure form and in pharma-
ceutical formulation. The HPLC method was devel-
oped by using column (Hyper ODS2 C18), UV detec-
tion at 260 nm at a flow rate of 1.2 ml/min and iso-
tonic composition of methanol and phosphate buffer 
(90:10) as mobile phase. The method was validated 
by using various validation parameters like accuracy, 
precision, linearity, specificity in an analytical solu-
tion. This method was rapid, simple and has great 
sensitivity and accuracy. The proposed method 
makes use of simple reagents, which an ordinary an-
alytical laboratory can afford. Hence the method can 
also be applied for routine estimation of Tenofovir in 
the formulation. This work can be further extended to 
study the applicability of this method to determine 
Tenofovir in biological fluids. 
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